3 recruiting, 1 active not recruiting. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Recruiting 3, Active not recruiting 1 |
Follow Hormone Sensitive Prostate Cancer: new trials by email Literature Review of Hormone Sensitive Prostate Cancer trials Research Report on Hormone Sensitive Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. Mevrometostat, Placebo, Enzalutamide - Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer | Phase 3 | Recruiting | Pfizer | 1000 | 2025-09-28 | 2026-10-14 |
| Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC Docetaxel, Rezvilutamide - Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer | Phase 3 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 200 | 2023-08-01 | 2023-08-09 |
| Metastasis-directed Therapy for Oligorecurrent Prostate Cancer Radiotherapy (SBRT) and/or surgery (metastasectomy), Androgen deprivation therapy, Androgen receptor targeted therapy - Prostate Cancer, Prostate Cancer Recurrent | Phase 3 | Recruiting | Universitaire Ziekenhuizen KU Leuven | 873 | 2022-04-20 | 2024-07-03 |
| Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) Enzalutamide, Placebo (No longer applicable in Open Label study period), Leuprolide Open Label - Hormone Sensitive Prostate Cancer, Prostate Cancer | Phase 3 | Active not recruiting | Pfizer | 1068 | 2014-12-17 | 2026-10-26 |
Prostatic Neoplasms (4) · Neoplasm Metastasis (1)
Genital Diseases (4) · Genital Diseases, Male (4) · Genital Neoplasms, Male (4) · Male Urogenital Diseases (4) · Neoplasms (4) · Neoplasms by Site (4) · Prostatic Diseases (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
enzalutamide (2) · Androgen Antagonists (1) · Docetaxel (1) · Leuprolide (1) · Metastasectomy (1) · PF06821497 (1) · Radiosurgery (1) · Radiotherapy (1) · luprolide acetate gel depot (1)
Pfizer (2) · The First Affiliated Hospital with Nanjing Medical University (1) · Universitaire Ziekenhuizen KU Leuven (1)
Australia (2) · Belgium (2) · Brazil (2) · Canada (2) · China (2) · Finland (2) · France (2) · Italy (2) · Netherlands (2) · Poland (2) · Slovakia (2) · South Korea (2) · Spain (2) · Taiwan (2) · United Kingdom (2)
Lixxin Hua (1)
PMID 34385241, PMID 36503429, PMID 37119051, PMID 37851874, PMID 38320501, PMID 38421243, PMID 38421252, PMID 40140551, PMID 41124201, PMID 41349040, PMID 41364813, PMID 42333826